Among them, one study conducted by Chen and colleagues [30] reported the median OS of newly diagnosed AML patients was 12.0±1.7 months with HAG treatment and OS was significantly correlated with age, initial karyotype, PS and gene mutations (NPM1, FLT-ITD and DNMT3A) at diagnosis. This evidence concerns the gene DNMT3A and acute myeloid leukemia.